Perspective Therapeutics (CATX) Income from Continuing Operations (2010 - 2026)
Perspective Therapeutics (CATX) reported Income from Continuing Operations of 28925000.0 for Q1 2026, down 59.13% on a YoY basis from 70772610.71 in Q1 2025, and up 24.44% sequentially from 38283000.0 in Q4 2025.
Perspective Therapeutics (CATX) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Perspective Therapeutics (CATX) has 17 years of Income from Continuing Operations data on file, last reported at 28925000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 59.13% year-over-year to 28925000.0; the trailing twelve-month figure through Mar 2026 stood at 115176000.0 (down 33.4% YoY), and the FY2025 full-year result was 104428000.0, down 30.55% from the prior year.
- Income from Continuing Operations grew to 28925000.0 in Q1 2026, from 38283000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 371000.0 in Q1 2023 to a low of 41828000.0 in Q4 2024.
- A 5-year average of 15919647.06 and a median of 11825000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations jumped 72.46% in 2023 and sank 3087.33% in 2024, its largest moves.
- Tracing CATX's Income from Continuing Operations over 5 years: stood at 7335000.0 in 2022, then sank by 148.98% to 18263000.0 in 2023, then plunged by 129.03% to 41828000.0 in 2024, then rose by 8.48% to 38283000.0 in 2025, then gained by 24.44% to 28925000.0 in 2026.
- Business Quant data shows CATX's Income from Continuing Operations at 28925000.0 in Q1 2026, 38283000.0 in Q4 2025, and 25969000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 380.70 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 199.50 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 273.95 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 411.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Perspective Therapeutics | 146.05 Mn | 146.05 Mn | - | -28.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.93 Mn |
| Dec 31, 2025 | -38.28 Mn |
| Sep 30, 2025 | -25.97 Mn |
| Jun 30, 2025 | -22.00 Mn |
| Mar 31, 2025 | -18.18 Mn |
| Dec 31, 2024 | -41.83 Mn |
| Sep 30, 2024 | -15.12 Mn |
| Jun 30, 2024 | -11.21 Mn |
| Mar 31, 2024 | -11.83 Mn |
| Dec 31, 2023 | -18.26 Mn |
| Sep 30, 2023 | -9.57 Mn |
| Jun 30, 2023 | -9.49 Mn |
| Mar 31, 2023 | -371,000.00 |
| Dec 31, 2022 | -7.34 Mn |
| Sep 30, 2022 | -7.49 Mn |
| Jun 30, 2022 | -3.43 Mn |
| Mar 31, 2022 | -1.35 Mn |
| Dec 31, 2021 | -1.60 Mn |
| Sep 30, 2021 | -2.59 Mn |
| Jun 30, 2021 | 362,000.00 |